Cardiff Oncology (CRDF) director receives 40,565 stock options grant

Rhea-AI Filing Summary

Cardiff Oncology director Lale White received a grant of stock options. The award covers 40,565 options to buy Cardiff Oncology common stock at an exercise price of $1.59 per share.

After this grant, White holds 199,246 derivative securities directly, with the options expiring on June 11, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider White Lale

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	40,565	$0.00	--

Holdings After Transaction: Stock Options — 199,246 shares (Direct, null)

Footnotes (1)

Key Figures

Stock options granted: 40,565 options Exercise price: $1.59 per share Expiration date: June 11, 2036 +1 more

4 metrics

Stock options granted 40,565 options Grant to director Lale White on June 11, 2026

Exercise price $1.59 per share Strike price for the granted stock options

Expiration date June 11, 2036 Expiry of granted stock options

Holdings after grant 199,246 derivative securities Total derivative position following the transaction

Key Terms

Stock Options, grant/award acquisition, exercise price, derivative securities

4 terms

Stock Options financial

"security_title: "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

exercise price financial

"conversion_or_exercise_price: "1.5900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"derivativeTransactionCount: 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

White Lale

(Last) (First) (Middle)

C/O CARDIFF ONCOLOGY, INC.

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.59	06/11/2026		A		40,565		06/11/2027	06/11/2036	Common Stock	40,565	$0	199,246	D

Explanation of Responses:

	/s/ Lale White	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Cardiff Oncology (CRDF) director Lale White report on this Form 4?

Lale White reported receiving a grant of 40,565 stock options in Cardiff Oncology. These options are a compensation-related award, not an open-market purchase or sale of common shares.

What is the exercise price of Lale White’s new Cardiff Oncology (CRDF) stock options?

The granted stock options have an exercise price of $1.59 per share. This is the price at which White can purchase Cardiff Oncology common stock if the options are exercised in the future.

When do Lale White’s Cardiff Oncology (CRDF) stock options expire?

The stock options granted to Lale White expire on June 11, 2036. If not exercised by that date, the options will lapse and no longer allow purchase of Cardiff Oncology common shares.

How many derivative securities does Lale White hold after this Cardiff Oncology (CRDF) grant?

Following this grant, Lale White directly holds 199,246 derivative securities tied to Cardiff Oncology common stock. This reflects the position after adding the 40,565 newly granted stock options.

Is Lale White’s Cardiff Oncology (CRDF) Form 4 transaction a market buy or sell?

No, the Form 4 reports a grant of stock options classified as an acquisition. It is a compensation grant, not an open-market buy or sell of Cardiff Oncology common stock.